跳至主要内容
临床试验/NCT03210558
NCT03210558已完成2 期

Effects of Moderately Increased Testosterone Concentration on Physical Performance and Behaviour in Healthy Women - a Double-blind, Randomized, Placebo-controlled Study

Karolinska University Hospital1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2017年5月26日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
48
试验地点
1
主要终点
Aerobic performance

研究概览

简要总结

Trial objectives and purpose: The primary aim is to study the effects of moderately increased testosterone concentration on aerobic performance (endurance running time to exhaustion), and secondary aims to investigate the effects on submaximal work on treadmill, anaerobic capacity, muscle strength, body composition, behaviour and well-being, blood parameters, steroid hormone profile, gynecological parameters and skeletal muscle parameters in young healthy women in a double-blind, randomized, placebo-controlled trial.

Treatment: Ten weeks of transdermal treatment with testosterone cream 10 mg daily or placebo cream in a randomized design (1:1).

Primary outcome: Aerobic performance (running time to exhaustion on treadmill)

Secondary outcomes:

  1. Submaximal work on treadmill (oxygen uptake, ventilation, heart rate, blood lactate and subjective rate of exhaustion)
  2. Anaerobic performance (Wingate test)
  3. Muscle strength (Cybex apparatus, force transducer, counter movement jump)
  4. Body composition (Dual X-ray Absorptiometry: muscle mass, fat mass, bone mass)
  5. Behaviour and well-being (Quality of life, Profile of mood state, Confidence Questionnaire, Aggression Questionnaire)
  6. Blood parameters (hemoglobin, hematocrit, reticulocytes, ferritin, CRP)
  7. Steroid hormone profile in blood and urine
  8. Gynecological evaluation (ovarian and endometrial variables on ultrasound)
  9. Skeletal muscle morphology, metabolic enzymes and muscle protein synthesis

Study population: Fifty healthy menstruating women will be included in the study and randomized to treatment with testosterone or placebo. Inclusion criteria: 18-35 yrs of age; body mass index (BMI) 19-25; non-smoking; a moderate to high self-reported level of recreational physical activity; not taking hormonal contraception and willing to use highly efficient non-hormonal contraception during the study (intrauterine device, bilateral tubal occlusion, vasectomised partner, same-sex partner, or sexual abstinence); accepting to not participate in any sports competitive event during the study period plus one month. Exclusion criteria: the presence of cardiovascular, liver, biliary or renal disease; hyperlipidemia; uncontrolled high blood pressure; endocrinological disorder; oligomenorrhea (menstrual intervals of more than 6 weeks) or amenorrhea (no menstruation for at least 3 months); pregnancy; a history of thromboembolic disorder; any malignancy; and intake of hormonal contraception the last two months prior to the study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

The testosterone cream and the placebo cream will be of identical appearance and will have the same texture to maintain double blind treatment.

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Group B

Placebo Comparator

Placebo cream

干预措施: Placebo cream (Drug)

Group A

Active Comparator

Testosterone cream 1% (Andro-Feme® )

干预措施: Testosterone cream 1% (Andro-Feme® ) (Drug)

结局指标

主要结局

Aerobic performance

时间窗: Baseline and 10 weeks of treatment

Change in endurance exercise time to exhaustion on treadmill

次要结局

  • Muscle mass(Baseline and 10 weeks of treatment)
  • Body fat percentage(Baseline and 10 weeks of treatment)
  • Bone mineral density(Baseline and 10 weeks of treatment)
  • Confidence(Baseline and 10 weeks of treatment)
  • Aggression(Baseline and 10 weeks of treatment)
  • Blood parameters(Baseline and 10 weeks of treatment)
  • Physical activity during one week before treatment and one week before the end of treatment(Baseline and 10 weeks of treatment)
  • Submaximal work on treadmill(Baseline and 10 weeks of treatment)
  • Psychological General Well-Being(Baseline and 10 weeks of treatment)
  • Mood(Baseline and 10 weeks of treatment)
  • Anaerobic performance (Wingate test)(Baseline and 10 weeks of treatment)
  • Muscle strength (knee extension torque)(Baseline and 10 weeks of treatment)
  • Functional power development-jump tests(Baseline and 10 weeks of treatment)
  • Steroid hormone profile in blood and urine(Baseline and 10 weeks of treatment)
  • Gynecological evaluation(Baseline and 10 weeks of treatment)
  • Skeletal muscle(Baseline and 10 weeks of treatment)

研究者

发起方
Karolinska University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Angelica Lindén Hirschberg

Professor

Karolinska University Hospital

研究点 (1)

Loading locations...

相似试验